Company intelligence / Profile preview

Vivacitas Oncology

Walnut Creek, California, United Statesvivaoncology.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Vivacitas Oncology’s lead asset AR‑67 has demonstrated activity in Phase II clinical studies for recurrent glioblastoma. The company leverages advanced imaging and AI-based response assessment through partnerships to improve trial outcomes. Early results suggest potential efficacy and improved tolerability over earlier camptothecin analogs. Further pivotal trials are anticipated but not yet reported as complete or published with final results.

Therapeutic areas: Oncology
Modalities: Small molecules (notably camptothecin analogs such as AR-67)Chemotherapy derivatives
Industry: Biotech

Drug pipeline

1 asset

AR-67

Phase 2

Indications: Glioblastoma, Solid tumors

Partnerships

Image Analysis Group (IAG) – collaboration for advanced imaging/AI-based response assessment in clinical trials of AR‑67 for brain cancer patients.

Beyond the preview

Go deeper on Vivacitas Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivacitas Oncology.

Explore the full profile